Why ACADIA Pharmaceuticals (ACAD) Gapped Higher


 
 
02:02 09/23/2018

After an incredible run on its Parkinson’s disease Psychosis (PDP) drug, ACADIA Pharmaceuticals [NASDAQ:ACAD) plummeted in recent months.

All thanks to a CNN report that highlighted a growing number of patient deaths and adverse effects, potentially related to the ACAD drug, Nuplazid. In fact, according to the report, more than 1,000 patients continued to experience hallucinations. More than 700 had died.

And, according to the report, medical experts said the drug was “approved too quickly.”

Understandably, that didn’t sit well with investors.

However, it appears the U.S. FDA just quieted those very concerns. In fact, the regulator said it couldn’t identify “any new or unexpected safety findings with Nuplazid, or findings that are inconsistent with the established safety profile currently described in the drug label.”


This article has been provided by a Chasing Markets contributor. All content submitted by this author represent their personal opinions, and should be considered as such for entertainment purpose only. All opinions expressed are those of the writer, and may not necessarily represent fact, opinions, or bias of Chasing Markets.
Most Read